

letter to the editor

# Comment on: Stress-induced hyperglycemia and expression of glucose cell transport genes in skeletal muscle of critically ill patients: a cross-sectional study

Raahin Rahim<sup>1</sup>

<https://orcid.org/0009-0000-9300-3689>

Hoorain Talpur<sup>2</sup>

<https://orcid.org/0009-0002-9689-5584>

Fatima Khurshid<sup>3</sup>

<https://orcid.org/0009-0007-3610-365X>

<sup>1</sup> Jinnah Sindh Medical University, Karachi, Pakistan.

<sup>2</sup> Ibn-e-Sina University, Mirpurkhas, Pakistan

<sup>3</sup> Karachi Medical and Dental College, Karachi, Pakistan

Dear Editor,

We read with interest the paper by Bellaver and cols., entitled “Stress-induced hyperglycemia and expression of glucose cell transport genes in skeletal muscle of critically ill patients: a cross-sectional study” (1). This research provides useful information about metabolic changes in critical illness. The author presents a variety of perspectives with fairness and detail, maintaining a praiseworthy balance. We agree with the well-founded conclusion that *IRS1* was downregulated in patients with stress-induced hyperglycemia; however, some methodological weaknesses have been encountered, which deserve mention.

Initially, it is not established whether patients on corticosteroids or with liver dysfunction were excluded or controlled. Both are prevalent and independently affect glucose metabolism. Stress hyperglycemia was described by Marik and cols. (2) as a multifactorial physiologic response, partially mediated by hepatic gluconeogenesis and modulated by endogenous and exogenous corticosteroids. Without controlling for these variables, ascribing *IRS1* downregulation to stress-induced hyperglycemia alone is doubtful.

Secondly, the study is narrowly targeted on four genes (*IRS1*, *IRS2*, *SLC2A1*, and *SLC2A4*), when the intricacy of insulin signaling is well established. More global transcriptomic or pathway-based strategies would have given a much broader molecular understanding of alterations. Vorotnikov and cols. note that insulin resistance emerges from various interacting regulatory nodes beyond those discussed here, validating the necessity for OMICS-level analysis in such intricate pathophysiologic states (3).

Thirdly, due to the cross-sectional nature of the study, it remains uncertain if *IRS1* downregulation is a response that is acute or representative of pre-existing susceptibility. Rung and cols. recognized a variant close to the *IRS1* locus (rs2943641) that correlated with decreased *IRS1* expression and insulin resistance, independent of acute illness (4). This introduces the likelihood that there are genetic underpinnings to what is observed. Moreover, inflammation, characteristic of critical illness, was not controlled for. Pro-inflammatory signaling, particularly by the c-Jun N-terminal kinase (JNK) pathway, has been shown to suppress *IRS1* activation. Hommelberg and cols. illustrated that inhibition of JNK maintains *IRS1* function in the presence of inflammation and, by implication, could contribute to decreased *IRS1* expression in this group (5). Cumulatively, these variables defy crediting *IRS1* downregulation solely to hyperglycemia.

In conclusion, while this study addresses an important question, future research would benefit from broader molecular profiling, inclusion of inflammatory markers, and longitudinal designs to better clarify causality and gene regulation in stress hyperglycemia.

Received on Jul/21/2025  
Accepted on Aug/1/2025

DOI: 10.20945/2359-4292-2025-0321

**Correspondence to:**

Raahin Rahim  
raahinrahim@gmail.com



This is an open-access article distributed under the terms of the Creative Commons Attribution License

**Disclosure:** no potential conflict of interest relevant to this article was reported.

**Data availability:** datasets related to this article will be available upon request to the corresponding author.

## REFERENCES

1. Bellaver P, Crispim D, Henrique LR, Leitão CB, Schaeffer AF, Rech TH, et al. Stress-induced hyperglycemia and expression of glucose cell transport genes in skeletal muscle of critically ill patients: a cross-sectional study. *Arch Endocrinol Metab.* 2025;69(2):e240417. doi: 10.20945/2359-4292-2024-0417
2. Marik PE, Bellomo R. Stress hyperglycemia: an essential survival response! *Crit Care.* 2013;17(2):305. doi: 10.1186/cc12514
3. Vorotnikov AV, Popov DV, Makhnovskii PA. Signaling and Gene Expression in Skeletal Muscles in Type 2 Diabetes: Current Results and OMICS Perspectives. *Biochemistry (Mosc).* 2022;87(9):1021-1034. doi: 10.1134/S0006297922090139
4. Rung J, Cauchi S, Albrechtsen A, Shen L, Rocheleau G, Cavalcanti-Proença C, et al. Genetic variant near *IRS1* is associated with type 2 diabetes, insulin resistance and hyperinsulinemia. *Nat Genet.* 2009;41(10):1110-5. doi: 10.1038/ng.443. Erratum in: *Nat Genet.* 2009;41(10):1156.
5. Hommelberg PP, Langen RC, Schols AM, Mensink RP, Plat J. Inflammatory signaling in skeletal muscle insulin resistance: green signal for nutritional intervention? *Curr Opin Clin Nutr Metab Care.* 2010;13(6):647-55. doi: 10.1097/MCO.0b013e32833f1acd